Ligand ID: 4PZ Drugbank ID: DB01213(Fomepizole) Indication:Antizol is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 3E4E_A_4PZA501_1 (CYTOCHROME P450 2E1) | 2gri | NSP3 (SARSr) | 3 / 3 | ALA A 61THR A 65CYH A 40 | 0.66A | 13.18 | None | ||
![]() | 3E4E_A_4PZA501_1 (CYTOCHROME P450 2E1) | 5c8u | GUANINE-N7METHYLTRANSFERASE (SARSr-CoV) | 3 / 3 | ALA B 482THR B 475CYH B 452 | 1.52A | 21.25 | NoneNone ZN B 603 (-2.4A) | ||
![]() | 3E4E_A_4PZA501_1 (CYTOCHROME P450 2E1) | 6jyt | HELICASE (SARSr) | 3 / 3 | ALA B 407THR B 380CYH B 309 | 1.22A | 22.15 | None | ||
![]() | 3E4E_A_4PZA501_1 (CYTOCHROME P450 2E1) | 6jyt | HELICASE (SARSr-CoV) | 3 / 3 | ALA B 134THR B 137CYH B 112 | 1.08A | 22.15 | None | ||
![]() | 3E4E_B_4PZB501_1 (CYTOCHROME P450 2E1) | 6m71 | NSP12 (SARS-CoV-2) | 3 / 3 | ALA A 585THR A 582CYH A 482 | 1.10A | 19.83 | None | ||
![]() | 3E4E_A_4PZA501_1 (CYTOCHROME P450 2E1) | 6m71 | NSP12 (SARS-CoV-2) | 3 / 3 | ALA A 585THR A 582CYH A 482 | 1.01A | 19.83 | None | ||
![]() | 3E4E_B_4PZB501_1 (CYTOCHROME P450 2E1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 3 / 3 | ALA C 139THR C 102CYH C 148 | 1.09A | 20.30 | None | ||
![]() | 3E4E_B_4PZB501_1 (CYTOCHROME P450 2E1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 3 / 3 | ALA B 139THR B 102CYH B 148 | 1.10A | 20.30 | None | ||
![]() | 3E4E_B_4PZB501_1 (CYTOCHROME P450 2E1) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 3 / 3 | ALA A 139THR A 102CYH A 148 | 1.09A | 20.30 | None | ||
![]() | 3E4E_B_4PZB501_1 (CYTOCHROME P450 2E1) | 6wrh | PEPTIDASE C16 (SARS-CoV-2) | 3 / 3 | ALA A 139THR A 102CYH A 148 | 1.14A | 21.04 | None | ||
![]() | 3E4E_A_4PZA501_1 (CYTOCHROME P450 2E1) | 6xez | NSP13 (SARS-CoV-2) | 3 / 3 | ALA F 134THR F 137CYH F 112 | 0.89A | 21.37 | None | ||
![]() | 3E4E_A_4PZA501_1 (CYTOCHROME P450 2E1) | 6xez | NSP12 (SARS-CoV-2) | 3 / 3 | ALA A 585THR A 582CYH A 482 | 0.92A | 19.62 | None | ||
![]() | 3E4E_A_4PZA501_1 (CYTOCHROME P450 2E1) | 7btf | NSP12 (SARS-CoV-2) | 3 / 3 | ALA A 585THR A 582CYH A 482 | 1.00A | 19.83 | None | ||
![]() | 3E4E_B_4PZB501_1 (CYTOCHROME P450 2E1) | 7btf | NSP12 (SARS-CoV-2) | 3 / 3 | ALA A 585THR A 582CYH A 482 | 1.10A | 19.83 | None | ||
![]() | 3E4E_A_4PZA501_1 (CYTOCHROME P450 2E1) | 7bv1 | NSP12 (SARS-CoV-2) | 3 / 3 | ALA A 585THR A 582CYH A 482 | 0.99A | 19.85 | None | ||
![]() | 3E4E_A_4PZA501_1 (CYTOCHROME P450 2E1) | 7bv1 | NSP12 (SARS-CoV-2) | 3 / 3 | ALA A 449THR A 556CYH A 669 | 1.18A | 19.85 | None | ||
![]() | 3E4E_B_4PZB501_1 (CYTOCHROME P450 2E1) | 7bv1 | NSP12 (SARS-CoV-2) | 3 / 3 | ALA A 585THR A 582CYH A 482 | 1.01A | 19.85 | None | ||
![]() | 3E4E_A_4PZA501_1 (CYTOCHROME P450 2E1) | 7bv2 | NSP12 (SARS-CoV-2) | 3 / 3 | ALA A 449THR A 556CYH A 669 | 1.18A | 19.85 | None |